Journal article

PD-1 blockade potentiates HIV latency reversal ex vivo in CD4( ) T cells from ART-suppressed individuals

Remi Fromentin, Sandrina DaFonseca, Cecilia T Costiniuk, Mohamed El-Far, Francesco Andrea Procopio, Frederick M Hecht, Rebecca Hoh, Steven G Deeks, Daria J Hazuda, Sharon R Lewin, Jean-Pierre Routy, Rafick-Pierre Sekaly, Nicolas Chomont

Nature Communications | NATURE PUBLISHING GROUP | Published : 2019

University of Melbourne Researchers

Grants

Awarded by Delaney AIDS Research Enterprise (DARE) to Find a Cure


Awarded by NIH


Awarded by Foundation for AIDS Research (amfAR Research Consortium on HIV Eradication)


Awarded by Canadian Institutes for Health Research


Awarded by CIHR


Awarded by CANFAR


Awarded by IAS


Awarded by UCSF/Gladstone Institute of Virology & Immunology CFAR


Awarded by CFAR Network of Integrated Systems


Awarded by Delaney AIDS Research Enterprise (DARE)


Awarded by amfAR Institute for HIV Cure Research


Awarded by Quebec Health Research Fund (FRQS)


Funding Acknowledgements

The authors thank the participants who have generously donated samples for this study. The authors thank Moti Ramgopal, Brenda Jacobs, Mario Legault, Guillaume Theriault, Catalin Mihalcioiu, and Josee Girouard for recruitment and clinical assistance with study participants, Gordon Freeman for providing the PD-L1 chimeric protein, Sheri Dubey and Danilo Casimiro for cytokines quantifications, Jonathan Karn, Curtis Dobrowolski, Marion Pardons for assistance with P-TEFb measurements and Mariam Lawani, Wendy Picano, and Hawley Rigsby for technical assistance. We also thank the flow cores at UCSF, VGTI Florida (Yu Shi and Kim Kusser) and at the CRCHUM (Dominique Gauchat and Annie Gosselin) for cell sorting and the NC3 core at the CRCHUM (Olfa Debbeche). The authors thank Marta Massanella and the members of the Cleveland Immunopathogenesis Consortium for advice and helpful discussions. This work was supported the Delaney AIDS Research Enterprise (DARE) to Find a Cure 1U19AI096109 and UM1AI126611, NIH grant 1R21AI113096, by the Foundation for AIDS Research (amfAR Research Consortium on HIV Eradication 108687-54-RGRL and 108928-56-RGRL), by the Canadian Institutes for Health Research (#364408), by The Canadian HIV Cure Enterprise Team Grant (Cancure) from the CIHR in partnership with CANFAR and IAS (HIG-133050), and by the Reseau SIDA maladies infectieuses (FRQ-S). The SCOPE cohort was supported the UCSF/Gladstone Institute of Virology & Immunology CFAR (P30 AI027763) and the CFAR Network of Integrated Systems (R24 AI067039). Additional support was provided by the Delaney AIDS Research Enterprise (DARE; AI096109, A127966) and the amfAR Institute for HIV Cure Research (amfAR 109301). S.R.L. is supported by a practitioner fellowship from the National Health and Medical Research Council (NHMRC) of Australia. J.P.R. holds the Louis Lowenstein Chair in Hematology & Oncology in the Faculty of Medicine at McGill University. N.C. is supported by a Research Scholar Career Award of the Quebec Health Research Fund (FRQS, #30950).